Get the Stockscreener App
0.8399
1.31%
0.0109
Pre-market:
.84
0.000100
+0.01%
Citius Oncology Inc stock is traded at $0.8399, with a volume of 48,237.
It is up +1.31% in the last 24 hours and down -10.63% over the past month.
Citius Oncology Inc is a biopharmaceutical company focused on developing and commercializing targeted oncology therapies.The Company centers on achieving a market position by advancing therapies with reduced development and clinical risks, and competitive advantages supported by intellectual property and regulatory exclusivity protection. This includes new formulations of previously approved drugs with substantial existing safety and efficacy data or expanded indications for approved therapies. The company focused on key geographies and stakeholders, majorly on cancer centers and patients.
See More
Previous Close:
$0.829
Open:
$0.817
24h Volume:
48,237
Relative Volume:
0.22
Market Cap:
$78.09M
Revenue:
$5.61M
Net Income/Loss:
$-42.51M
P/E Ratio:
-1.8024
EPS:
-0.466
Net Cash Flow:
$-16.86M
1W Performance:
-12.81%
1M Performance:
-10.63%
6M Performance:
-25.67%
1Y Performance:
-7.70%
1-Day Range:
$0.7942
$0.84
1-Week Range:
$0.7501
$0.8844
52-Week Range:
$0.4912
$6.19
Citius Oncology Inc Stock (CTOR) Company Profile
Name
Citius Oncology Inc
Sector
Phone
(908) 967-6677
Address
11 COMMERCE DRIVE, CRANFORD
Compare CTOR vs TAK, HLN, TEVA, ZTS, UTHR
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CTOR
Citius Oncology Inc
|
0.8399 | 77.08M | 5.61M | -42.51M | -16.86M | -0.466 |
TAK
Takeda Pharmaceutical Co Adr
|
16.25 | 52.07B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.29 | 41.28B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.07 | 39.78B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
81.32 | 33.57B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
568.43 | 24.02B | 3.17B | 1.29B | 1.01B | 27.09 |
Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-23-25 | Upgrade | Maxim Group | Hold → Buy |
| Nov-27-24 | Initiated | Maxim Group | Buy |
Citius Oncology Inc Stock (CTOR) Latest News
Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts? - Yahoo Finance
TENK News & Events - Intellectia AI
Citius Pharmaceuticals (NASDAQ: CTXR) registers 5.43M resale shares from warrants - Stock Titan
Citius Oncology (CTOR) registers 6.82M warrant shares; May 2026 financing steps - Stock Titan
CTOR Technical Analysis | Trend, Signals & Chart Patterns | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
CTXR Stock Price, Quote & Chart | CITIUS PHARMACEUTICALS INC (NASDAQ:CTXR) - ChartMill
Citius Oncology (NASDAQ: CTOR) majority approves warrant and conversion issuances - Stock Titan
Citius Pharmaceuticals Reports Increased Losses in Q2 FY 2026 - Intellectia AI
Is Citius Pharmaceuticals (CTXR) Undervalued After Q2 FY2026 Upd - GuruFocus
Citius Oncology Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Citius Oncology reports $5.6M H1 revenue, $26.6M Q2 net loss; secures up to $36.5M financing - TradingView
[8-K] CITIUS ONCOLOGY, INC. Reports Material Event - Stock Titan
Citius Pharmaceuticals (CTXR) logs $5.6M LYMPHIR sales, deeper losses in Q2 2026 - Stock Titan
CITIUS ONCOLOGY, INC. 3Q 2026: Revenue $1.67M, EPS $(0.27) — 10-Q Summary - TradingView
Citius Oncology 2Q Loss/Shr 27c >CTOR - Moomoo
Citius Pharmaceuticals (CTXR) starts LYMPHIR sales but faces heavy loss and going concern risk - Stock Titan
Citius Oncology (NASDAQ: CTOR) flags going concern, adds $25.0 million loan - Stock Titan
Citius Pharmaceuticals, Inc. Reports Fiscal Second Quarter 2026 Financial Results and Provides Business Update - PR Newswire
Armistice Capital (CTOR) files 9.99% ownership disclosure - Stock Titan
TradingKey - TradingKey
Citius Oncology, Inc. (CTOR) Eps Diluted (TTM) - Zacks Investment Research
Citius Pharmaceuticals Announces Third Amendment to Promissory Note with Citius Oncology – SEC Filing Details - Minichart
Citius Pharmaceuticals Amends Promissory Note to Enhance Flexibility - TipRanks
Citius Oncology Inc expected to post a loss of 1 cent a shareEarnings Preview - TradingView
Citius Pharmaceuticals (CTXR) adds $0.90 share conversion to $3.8M note - Stock Titan
What Citius Oncol (CTOR) is doing to protect its market share (On the Radar) 2026-05-08Revenue Growth Stocks - newser.com
Financing package boosts Lymphir commercial push - The Pharma Letter
Citius Pharmaceuticals subsidiary raises up to 36.5 million dollars for LYMPHIR commercialization - Traders Union
Citius Oncology Secures New Financing to Support LYMPHIR - TipRanks
Citius Oncology Secures $36.5 Million Financing to Accelerate LYMPHIR® Commercialization and Growth - Minichart
Citius raises $36.5m for Lymphir commercialisation - Yahoo Finance
Citius Oncology Secures Up to $25M Term Loan and $11.5M Warrant Proceeds to Fund Commercialization - TradingView
Press Release: Citius Oncology, Inc. Secures Up to $36.5 Million in Debt and Equity Capital to Accelerate LYMPHIR(R) Commercialization - Moomoo
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Quantisnow
Citius Oncology (NASDAQ: CTOR) registers 6.82M warrant shares, updates LYMPHIR trials and launch - Stock Titan
Citius Oncology, Inc. announced that it expects to receive $36.5 million in funding - marketscreener.com
Citius Oncology Faces Nasdaq Non-Compliance, Delisting Risk Looms - TipRanks
CTOR Stock Price, Quote & Chart | CITIUS ONCOLOGY INC (NASDAQ:CTOR) - ChartMill
Citius Oncology sees first international shipment of LYMPHIR to Europe - ROI-NJ
Citius Oncology, Inc.'s (NASDAQ:CTOR) Path To Profitability - simplywall.st
Citius Expands LYMPHIR Access with First European Shipment - TipRanks
Citius Oncology Begins First European Expansion of LYMPHIR - TipRanks
Citius Oncology ships first international order of LYMPHIR to Europe - TradingView
Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN
Citius Oncology Ships First International Order of LYMPHIR™ to E - GuruFocus
Citius Oncology Ships First International Order of LYMPHIR™ to Europe - ChartMill
Citius Oncology, Inc. Receives Nasdaq Compliance Notice for CTOR Common Stock – Form 8-K April 2026 Filing - Minichart
Citius Oncology Disclosed Failure to Satisfy a Continued Listing Rule or Standard - TradingView
Nasdaq warns Citius Oncology (NASDAQ: CTOR) on sub-$1 bid price and delisting risk - Stock Titan
Citius Pharmaceuticals Announces Closing of Registered Direct Offering of $5 Million Priced At-The-Market Under Nasdaq Rules - marketscreener.com
Citius taps $5M to fund LYMPHIR launch and pipeline payments - Stock Titan
Citius Oncology Inc Stock (CTOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.92%
4.44%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):